Andrew Williams, MD
Internal Medicine · Pasadena, CANPI 1245641869
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $67,025 of the $67,235 with a category attached, or 99.7%. Astrazeneca UK Limited accounts for 73.2% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $23,629, 5.4 times the $4,382 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $738.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$49K
- Astrazeneca AB$8K
- Sanofi US Services Inc.$6K
- AstraZeneca$2K
- Bioverativ Therapeutics Inc.$2K
- Eisai Inc.$563
- plus $168 from 4 others
Across 21 payments — averaging $1661.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB Biosciences Inc.$10K
- Novartis$7K
- Regeneron$4K
- Eli Lilly$4K
- Bristol Myers Squibb$3K
- Dompe Farmaceutici S.p.a.$3K
- plus $3K from 3 others
What the payments were for
- Consulting fees$67,025100%
- Food & beverage$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 59 | $49,220 |
| Astrazeneca AB | 9 | $8,029 |
| Sanofi US Services Inc. | 6 | $5,661 |
| AstraZeneca | 4 | $2,042 |
| Bioverativ Therapeutics Inc. | 3 | $1,554 |
| Eisai Inc. | 1 | $563 |
| Pfizer | 3 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Johnson & Johnson | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIVV020$3,911
How this compares
$67,235 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $334 |
| Carvedilol | 14 | $28 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Pasadena
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.